Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis

Full text
Salles, Geisa Nogueira [1, 2, 3] ; Calio, Michele Longoni [2] ; Afewerki, Samson [4, 5] ; Pacheco-Soares, Cristina [3] ; Porcionatto, Marimelia [2] ; Holscher, Christian [1] ; Lobo, Anderson O. [6, 7, 8]
Total Authors: 7
[1] Univ Lancaster, Fac Hlth & Med, Div Biomed & Life Sci, Lancaster LA1 4YQ - England
[2] Univ Fed Sao Paulo, Escola Paulista Med, Dept Biochem, Neurobiol Lab, BR-0402100 Sao Paulo - Brazil
[3] Univ Vale Paraiba, Inst Pesquisa & Desenvolvimento, Lab Dynam Cellular Compartments, BR-12244000 Sao Jose Dos Campos, SP - Brazil
[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Engn Med, Cambridge, MA 02139 - USA
[5] MIT, Harvard MIT Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 - USA
[6] MIT, Dept Chem, Cambridge, MA 02139 - USA
[7] Univ Brasil, Inst Sci & Technol, BR-08230030 Sao Paulo - Brazil
[8] UFPI Fed Univ Piaui, LIMAv Interdisciplinary Lab Adv Mat, PPGCM Mat Sci & Engn Grad Program, BR-64049550 Teresina, Piaui - Brazil
Total Affiliations: 8
Document type: Journal article
Source: ACS APPLIED MATERIALS & INTERFACES; v. 10, n. 43, p. 36693-36702, OCT 31 2018.
Web of Science Citations: 4

Delivering drugs and agents to the brain is a huge challenge, especially for chronic neurodegenerative disorders, such as Alzheimer's disease (AD). For this, prolonged and sustained release methods to increase brain uptake represent an impacting concept. The bioresorbable polymer poly-lactic acid (PLA) has high potential for medical implants; at the same time, glucagon-like peptide-1 (GLP-1) analogues have considerable neuroprotective attributes and represent a therapeutic strategy for AD. Here, a biodevice is produced by electrospinning PLA with a GLP-1 analogue (liraglutide, LG), coated with a thin layer of gelatin. The biodevice is subcutaneously implanted in a transgenic mouse model of AD and LG is released for 14 days in mice serum. After 4 weeks of implantation, crucial hallmarks of the AD are highly diminished: hippocampal senile amyloid beta plaque load and neuroinflammatory markers. Furthermore, neurogenesis is enhanced in the subventricular zone, an important neurogenic niche in the brain. The designed biodevice holds great promise for being an affordable candidate to act as a prolonged drug provider, promoting LG mission through increasing its lifetime, constituting a relevant approach for old and impaired brain. (AU)

FAPESP's process: 14/20561-0 - Bioreabsorbable polymeric nanodevice as peptide controlled delivery system to Alzheimer's disease therapy
Grantee:Geisa Nogueira Salles
Support type: Scholarships in Brazil - Doctorate (Direct)